List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1304 studies with search of: Open Studies | "Lymphoma"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Unknown † Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
2 Recruiting Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Low Grade B-cell Lymphoma, Not Otherwise Specified
Intervention: Drug: Clofarabine
3 Unknown † Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   Burkitt's Leukemia;   Mediastinal Neoplasms;   Lymphoblastic Lymphoma;   Large Cell Anaplastic Lymphoma
Interventions: Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone/Prednisolone;   Drug: VP16;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: G-CSF;   Drug: Rituximab;   Drug: Vincristine/Vindesine;   Procedure: Irradiation (in specific conditions)
4 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Conditions: Enteropathy-Associated T-Cell Lymphoma;   Anaplastic Large-Cell Lymphoma;   Cutaneous T-Cell Lymphoma;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome;   Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox
5 Recruiting Tandem Auto-Allo Transplant for Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
6 Recruiting Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: azacitidine;   Drug: bortezomib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Genetic: protein expression analysis;   Genetic: gene expression analysis;   Genetic: DNA methylation analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Genetic: microarray analysis;   Other: enzyme-linked immunosorbent assay;   Other: liquid chromatography;   Other: mass spectrometry;   Genetic: reverse transcriptase-polymerase chain reaction
7 Not yet recruiting A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat
8 Recruiting Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Imexon
9 Recruiting Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Conditions: Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
10 Recruiting Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma
Interventions: Drug: azacitidine;   Drug: lenalidomide
11 Recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
12 Recruiting Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Follicular Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Mantle Cell Lymphoma;   Prolymphocytic Leukemia;   Large Cell Lymphoma
Intervention: Biological: CART-19
13 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
14 Recruiting RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
Conditions: Peripheral T Cell Lymphoma Unspecified;   Anaplastic Large Cell Lymphoma, ALK-negative;   Angioimmunoblastic T Cell Lymphoma;   Cutaneous T Cell Lymphoma
Intervention: Drug: RAD001 (Everolimus)
15 Recruiting Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
16 Recruiting Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: Drug: carfilzomib;   Other: laboratory biomarker analysis
17 Recruiting Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: panobinostat;   Other: laboratory biomarker analysis;   Genetic: western blotting;   Genetic: DNA analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: immunohistochemistry staining method
18 Recruiting Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Biological: DI-Leu16-IL2 immunocytokine;   Biological: rituximab;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Genetic: reverse transcriptase-polymerase chain reaction
19 Unknown † Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Lymphoma, Large Cell;   Diffuse, Mantle Cell Lymphoma, Lymphoma;   Follicular Lymphoma;   Large B-Cell, Diffuse
Interventions: Drug: SyB L-0501;   Drug: Rituximab
20 Recruiting Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Biological: dendritic cell vaccine therapy;   Procedure: cryotherapy;   Biological: pneumococcal polyvalent vaccine;   Other: laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Biological: autologous dendritic cell-tumor fusion vaccine

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services